Immun4Cure Cohort of Autoimmune Diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a monocentric, prospective cohort at Montpellier University Hospital aiming to enroll 500 participants (450 with autoimmune diseases and 50 healthy controls) to create a rich biobank and data resource. The study collects longitudinal clinical data, multi-omic data (genomics, transcriptomics, proteomics, metabolomics, immunophenotyping), environmental exposure information, and various biospecimens. Healthy controls will provide baseline references through baseline and 12-month assessments. The project supports translational research and ancillary projects through standardized follow-up and sample collection over five years. Interventions are observational in nature, including blood collection, questionnaires, and examinations.

Why it matters

Who can join: the full rules

Inclusion Criteria Participants:

Group 1: RA

* Adults ≥18 years
* Patient followed as part of their MAI in one of the departments participating in the study at UHM
* Confirmed diagnosis according to international criteria :ACR/EULAR 2010

Group 2: LES

* Adults ≥18 years
* Patient followed as part of their MAI in one of the departments participating in the study at UHM
* Confirmed diagnosis according to international criteria :ACR/EULAR 2019

Group 3: SSc

* Adults ≥18 years
* Patient followed as part of their MAI in one of the departments participating in the study at UHM
* Confirmed diagnosis according to international criteria :ACR/EULAR 2013

Group 4: Healthy Controls

* Adults ≥18 years
* No symptoms of autoimmune disease
* No first-degree family history of autoimmune disease

Exclusion Criteria (all groupes):

* Patients who have refused or are unable to give informed consent
* Inability to follow the subject during the study period
* Participation in another interventional study that includes an exclusion period that is still ongoing
* Pregnant women
* Not affiliated with a social security scheme
* Patients without a national insurance number
* Persons under judicial protection, guardianship or trusteeship
* Persons deprived of their liberty

Where it's running

• CHU de Montpellier - CIMA
  Montpellier, France Recruiting

Study contacts

• Study coordinator: Charlotte KAAN
• Email: depotac@chu-montpellier.fr
• Phone: +334 67 33 48 53

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Test of HBM7020 in healthy adults and adults with autoimmune diseases

  This first-in-human study tests whether HBM7020 is safe and how it acts in the body for people with autoimmune diseases like RA, SLE, Sjögren's, and SSc compared with healthy volunteers.

  Recruiting Phase 1 Otsuka Pharmaceutical Development & Commercialization, Inc. · Brisbane, Queensland · NCT07649265

• Anti-CD19/BCMA universal CAR-T cell therapy for refractory autoimmune diseases

  This will try anti-CD19/BCMA universal CAR-T cell therapy in adults with refractory rheumatoid arthritis, dermatomyositis, systemic lupus, or systemic sclerosis to see if it is safe and can control their disease.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07558850

• Anti-CD19/BCMA U CAR-T cell therapy for relapsed or refractory autoimmune diseases

  This pilot will test whether anti-CD19/BCMA U CAR-T cells can help adults with relapsed or refractory autoimmune diseases such as SLE, systemic sclerosis, Sjögren's syndrome, and rheumatoid arthritis.

  Recruiting Early Phase 1 Changhai Hospital · Shanghai · NCT07246096

• Imaging in Inflammatory Heart Diseases linked to autoimmune disorders

  This study tests how well multimodality imaging (CMR, echocardiography, and PET) detects inflammation in people with suspected inflammatory heart or autoimmune rheumatic diseases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07077304

• Registry and biorepository for rheumatic diseases

  This study is collecting samples and health information from adults with rheumatic diseases at Yale clinics to help researchers learn more about these conditions and improve future treatments.

  Recruiting Yale University · New Haven, Connecticut · NCT04402086

• ABBV-519 in adults with SLE or RA: safety and how the drug moves through the body after IV and subcutaneous doses

  This early study tests how ABBV-519 behaves in the body and its safety for adults with SLE or RA after single escalating doses.

  Recruiting at 15 sites Phase 1 AbbVie · Anniston, Alabama and 14 other locations · NCT07607964

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.